Taking into consideration the promising activity of IL-15-expressing CAR-NKTs in patients with relapsed/refractory neuroblastoma, IL-12 engineering could represent the next step to manufacture long-term persisting innate cells for cancer immunotherapy in solid tumors. The gene discussed is IL15; the disease is neuroblastoma.